DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes

BACKGROUND: Use of dipeptidyl peptidase-4 inhibitors (DPP4-i) for the treatment of type 2 diabetes (T2D) has been associated with a possible increase in the risk for heart failure (HF). B-type natriuretic peptide (BNP), which is both a biomarker of HF and a hemodynamically active hormone, is a subst...

Descripción completa

Detalles Bibliográficos
Autores principales: Fadini, Gian Paolo, Bonora, Benedetta Maria, Albiero, Mattia, Zaninotto, Martina, Plebani, Mario, Avogaro, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301429/
https://www.ncbi.nlm.nih.gov/pubmed/28183314
http://dx.doi.org/10.1186/s12933-017-0507-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301429/
https://www.ncbi.nlm.nih.gov/pubmed/28183314
http://dx.doi.org/10.1186/s12933-017-0507-9

Ejemplares similares